Abstract:Introduction The right ventricle (RV) is implicated to varying degrees in inflammatory cardiomyopathies, with unique presentations and often poor prognoses. RV dysfunction in cardiac sarcoidosis (CS) can have multiple etiologies, including left-sided heart disease, lung disease, pulmonary hypertension, and importantly direct granulomatous inflammation of the RV. In fact, CS may present as a primary RV cardiomyopathy. Myocardial fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging can identify active inflammation in the RV. There exist limited data on clinical characteristics and long-term outcomes in patients with diagnosed CS and inflammatory RV involvement. Hypothesis We hypothesized that CS with RV involvement, defined by RV FDG uptake on PET imaging, would portend a greater risk of adverse cardiovascular outcomes. Methods We analyzed a retrospective cohort of patients with CS diagnosed by Heart Rhythm Society or Japanese Circulation Society criteria (n = 223, average age at diagnosis 52.3 years, 40% female, 48% non-White) who underwent cardiac PET imaging either pre- or post-treatment with immunosuppression. Presenting characteristics and clinical outcomes of patients with FDG uptake in the RV (RV-FDG+) at any timepoint were compared to those with only left ventricle (LV) FDG uptake (LV-FDG+) and no myocardial FDG uptake (FDG-). The primary outcome was a composite of left ventricular assist device placement, orthotopic heart transplant, or death; secondary outcome was post-treatment sustained ventricular arrhythmia. Chi-square and one-way analysis of variance were used to compare categorical and continuous variables, respectively; survival analysis used Kaplan-Meier method and compared via log-rank. Results Among the cohort, 62 patients were FDG-, 133 were isolated LV-FDG+, and 28 (12.6%) were RV-FDG+. There were no significant sex or race differences between the three groups. In the RV-FDG+ group, significantly more patients initially presented with heart failure (p = 0.04) but fewer presented with sustained ventricular arrhythmias (p = 0.04) across all three groups. At presentation, there was no difference in rates of complete heart block (p = 0.42) or LV ejection fraction less than 50% (p = 0.16). Survival analysis showed worse primary composite outcome free survival among the RV-FDG+ group compared to the other two but similar rate of new ventricular arrhythmia to LV-FDG+, both of which were worse than FDG-. (Figure 1). Conclusions RV FDG uptake on PET imaging in patients with CS is prevalent and is associated with an increased risk of incipient heart failure and adverse clinical outcomes. Cardiac PET imaging can help identify patients with CS involvement of the RV and thereby aid in prognostication.

Potential application of 68Ga-FAPI PET/CT for diagnosing cardiac sarcoidosis

The Potential Role of 18F-FDG PET/CT in Dermatomyositis with Cardiac Involvement: A Case Report

Intense 68Ga-OncoFAP Uptake as a New Promising Diagnostic Biomarker in Cardiac Sarcoidosis

In Vivo Fibroblast Activation of Systemic Sarcoidosis: A 68Ga-FAPI-04 PET/CT Imaging Study

Exploring the latest advances in 18F-FDG PET/CT and cardiac magnetic resonance for imaging for cardiac sarcoidosis diagnosis

FDG PET/CT Imaging of Sarcoidosis.

Physiological myocardial 18F-FDG uptake pattern in oncologic PET/CT: comparison with findings in cardiac sarcoidosis

Cardiac Sarcoidosis: Utilizing Cardiac MRI and PET-CT

Imaging of Cardiac Sarcoidosis: An Update and Future Aspects

AI-enabled CT-guided end-to-end quantification of total cardiac activity in 18FDG cardiac PET/CT for detection of cardiac sarcoidosis

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Diagnosis of Benign Pulmonary Lesions in Sarcoidosis

Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and Meta-Analysis

Diagnostic value of 18F-FDG PET/CT for Sarcoidosis

18F-FDG-PET in Finnish patients with clinical suspicion of cardiac sarcoidosis: Female sex and history of atrioventricular block increase the prevalence of positive PET findings

Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?

Revealing The Enigma Of Cardiac Sarcoidosis: The Crucial Significance Of Advanced Imaging Modalities- A Case Report

Comparing the diagnostic performance of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting cardiac sarcoidosis: A meta-analysis

Specific locations of myocardial inflammation and fibrosis are associated with higher risk of events in cardiac sarcoidosis

Not To Be Forgotten: Implications Of Right Ventricular Inflammation On Positron Emission Tomography In Cardiac Sarcoidosis

Meta-analysis of [18F]FDG-PET/CT in pulmonary sarcoidosis

An assessment of PET and CMR radiomic features for the detection of cardiac sarcoidosis